摘要
目的 :评价HP联合化疗方案治疗晚期难治性转移性乳腺癌的安全性 ,可行性及有效性。方法 :对 30例有可测量的病变 ,卡氏评分≥ 70分 ,曾经应用CMF、CAF方案治疗无效的乳腺癌患者行HP方案化疗。HCPT 8mg/m2 ivgttd1～ 5 ,DDP 15mg/m2 ivgttd1～ 5 ,2 1天为一周期。至少治疗 2个周期以上。结果 :全组 30例 ,CR 4例 ,PR 12例 ,总有效率 5 3 3%。毒副反应主要是白细胞及血小板下降 ,发生率分别为 80 %和 30 % ,白细胞Ⅲ、Ⅳ度毒性为 10 %和 6 7%。未见心肝肾重要脏器损害。结论 :HP方案治疗晚期难治性乳腺癌较为满意且安全可行。
Objective:To study the effects and side effects of HP regiment in the treatment of advanced or refractory breast cancer.Methods:HCPT 8mg/m 2 was given by intravenous infusion from day 1 to day 5, DDP 15mg/m 2 was given by intravenous infusion from day 1 to day 5; 21 days a cycles for more than two cycles.Results:In all 30 patients, 53 3% of response rate were achieved with 4 CR and 12 PR. Main toxicity were neutropenia and thrombocytopenis with occurrence rate of 80% and 30% respectively. But Ⅲ to Ⅳ neutropenia were 10% and 3 3%.Conclusion:HP regimen in the treatment of advanced breast cancer achieved a statisfied result and it is tolerable safely.
出处
《临床肿瘤学杂志》
CAS
2003年第2期112-113,共2页
Chinese Clinical Oncology
关键词
联合化疗
晚期乳腺癌
近期疗效
Combination chemotherapy
Advanced Breast Cancer
Short term Response
